Haemonetics (NYSE:HAE) reported Q3 2018 earnings this Morning, coming in at $0.62 per share, beating Wall Street’s estimates of $0.44 per Share. Revenue for the quarter came in at $234.04 million beating analyst estimates of $227.79 million Recent Insider Trading for Haemonetics (NYSE:HAE)
- On 1/2/2018 Mark W Kroll, Director, sold 7,118 with an average share price of $63.00 per share and the total transaction amounting to $448,434.00.
- On 12/1/2017 Pedro P Granadillo, Director, sold 7,118 with an average share price of $57.06 per share and the total transaction amounting to $406,153.08.
- On 11/16/2017 Ronald G Gelbman, Director, sold 5,440 with an average share price of $56.69 per share and the total transaction amounting to $308,393.60.
- On 11/14/2017 Willaim P Burke, CFO, sold 13,193 with an average share price of $54.04 per share and the total transaction amounting to $712,949.72.
- On 11/13/2017 Dan Goldstein, CAO, sold 4,691 with an average share price of $54.93 per share and the total transaction amounting to $257,676.63.
- On 11/10/2017 Susan Bartlett Foote, Director, sold 16,926 with an average share price of $54.19 per share and the total transaction amounting to $917,219.94.
Recent Trading for Haemonetics (NYSE:HAE) Shares of Haemonetics closed the previous trading session at 60.72 +0.00 0.00% with 63.650001525878906 shares trading hands.